A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Public ClinicalTrials.gov record NCT02224690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.
Study identification
- NCT ID
- NCT02224690
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Interventions
- GWP42003-P 20 mg/kg/day Dose Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2015
- Primary completion
- Mar 17, 2016
- Completion
- Mar 17, 2016
- Last update posted
- Sep 27, 2022
2015 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Atlanta | Georgia | 30328 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Ames | Iowa | 50010 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Lexington | Kentucky | 40536 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Saint Paul | Minnesota | 55102 | — |
| Not listed | St Louis | Missouri | 63131 | — |
| Not listed | Lebanon | New Hampshire | 03756 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | The Bronx | New York | 10467 | — |
| Not listed | Philadelphia | Pennsylvania | 19104-4399 | — |
| Not listed | Dallas | Texas | 75251 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Salt Lake City | Utah | 81143 | — |
| Not listed | Winchester | Virginia | 22601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02224690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2022 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02224690 live on ClinicalTrials.gov.